Dr. Moxit Shah — Diabetes, Thyroid & Weight Loss Endocrinologist in Ahmedabad

GLP-1 medicines have become one of the most important developments in modern obesity and weight-loss treatment.

Medicines such as semaglutide and liraglutide belong to the GLP-1 receptor agonist class. Tirzepatide is a related but slightly different medicine that acts on both GIP and GLP-1 receptors.

These medicines can reduce appetite, increase fullness, improve blood sugar control and help appropriately selected patients achieve significant weight loss.

But one of the most important questions is:

Who can actually take GLP-1 medicines for weight loss?

Not everyone who wants to lose weight needs a GLP-1 medicine. These are prescription treatments that should be considered after evaluating your weight, health conditions, medications, medical history and treatment goals.

What Are GLP-1 Agonists?

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced by the body.

GLP-1 receptor agonists mimic the action of this hormone.

They can:

Reduce appetite
Increase feelings of fullness
Slow gastric emptying
Improve glucose-dependent insulin secretion
Reduce inappropriate glucagon secretion
Reduce food intake
Improve blood glucose levels
Support weight loss

Common GLP-1-based medicines include semaglutide and liraglutide.

Tirzepatide is slightly different. It activates both GIP and GLP-1 receptors and is therefore called a dual GIP/GLP-1 receptor agonist.

The World Health Organization recognizes liraglutide, semaglutide and tirzepatide as medicines that can be used for long-term treatment of obesity in appropriately selected adults, alongside comprehensive lifestyle intervention.

Who Can Take GLP-1 Medicines for Weight Loss?

This is the most important part.

GLP-1-based weight-loss medicines may be considered for adults with obesity or overweight accompanied by weight-related health problems, depending on the specific medicine and applicable regulatory indication.

Current Indian CDSCO records for semaglutide weight-management formulations include adults with:

BMI ≥30 kg/m², or
BMI ≥27 kg/m² with at least one weight-related comorbidity

such as hypertension, type 2 diabetes or dyslipidemia.

Current Indian CDSCO records for tirzepatide similarly describe weight-management use in adults with BMI ≥30 kg/m², or ≥27 to <30 kg/m² with a weight-related comorbidity, alongside reduced-calorie diet and increased physical activity.

However, BMI is not the only factor a doctor should consider.

Can Someone With Overweight Take a GLP-1 Medicine?

Potentially, yes—but generally not simply because they want to lose a few kilograms.

For example, a person with overweight who also has conditions such as:

Type 2 diabetes
Prediabetes
Hypertension
High cholesterol
Obstructive sleep apnea
Cardiovascular disease
Fatty liver/metabolic complications

may be considered for medical weight-management treatment when the relevant criteria are met.

The 2025 Indian ESI obesity guideline update recommends considering pharmacotherapy at BMI >27 kg/m², or at BMI >25 kg/m² when an associated comorbidity is present, using an individualized approach.

This is an important distinction:

Not everyone with a few extra kilograms requires a GLP-1 medicine.

Can a Person With Obesity Take a GLP-1 Medicine?

Yes, obesity is one of the major clinical situations in which GLP-1-based pharmacotherapy may be considered.

Obesity is increasingly recognized as a chronic disease, rather than simply a cosmetic problem or a lack of willpower.

The WHO’s 2025 guideline conditionally recommends GLP-1 therapies as a long-term treatment option for adults living with obesity, while emphasizing diet, physical activity and professional support.

Can People With Diabetes Take GLP-1 Medicines?

Yes.

GLP-1-based medicines are particularly useful in selected people with type 2 diabetes and overweight or obesity because they can address both blood glucose and weight.

The 2026 American Diabetes Association Standards recommend considering obesity pharmacotherapy alongside lifestyle intervention in people with diabetes and overweight or obesity. They specifically identify semaglutide and tirzepatide as preferred high-efficacy options when appropriate.

For a patient with type 2 diabetes, the choice of treatment may also depend on:

HbA1c
Cardiovascular disease
Kidney disease
Current diabetes medications
Risk of hypoglycemia
Body weight
Treatment goals

Can GLP-1 Medicines Be Used Without Diabetes?

Yes.

This is a common misconception.

A person does not necessarily need diabetes to be considered for an obesity medicine.

Some semaglutide and tirzepatide formulations are approved for chronic weight management in appropriately selected adults with obesity or overweight with relevant weight-related conditions. Current Indian CDSCO records include weight-management indications for both semaglutide and tirzepatide.

The important question is not:

“Do I have diabetes?”

It is:

“Do I meet the clinical criteria for medical treatment of obesity or overweight, and is this particular medicine appropriate for me?”

Can Young Adults Take GLP-1 Medicines?

Some weight-management medicines have indications that include adolescents or younger age groups, depending on the specific medicine and country.

However, treatment in children and adolescents requires specialist assessment.

Factors such as:

Growth
Pubertal development
Nutrition
Psychological health
Family environment
Eating behavior
Underlying medical conditions

need to be considered.

Therefore, adults should not assume that a medicine used by them is automatically appropriate for their child.

Who Should NOT Take GLP-1 Medicines?

GLP-1-based medicines are not appropriate for everyone.

Important contraindications and precautions depend on the specific medicine, but doctors commonly need to consider:

Personal or family history of medullary thyroid carcinoma

Semaglutide- and tirzepatide-containing products carry important warnings related to thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, according to their prescribing information.

Pregnancy

GLP-1 therapies are generally not used for weight loss during pregnancy. WHO specifically notes that its obesity guideline does not cover pregnant women because these medicines have not been adequately tested in this population.

Severe gastrointestinal disease

Patients with significant gastrointestinal disorders, including severe gastroparesis, require careful assessment.

Previous pancreatitis

A history of pancreatitis requires individualized medical consideration.

Gallbladder disease

Doctors should consider the patient’s history of gallstones or gallbladder disease.

Certain medications

Patients taking insulin or sulfonylureas may need adjustment of those medicines because of the risk of hypoglycemia.

Is GLP-1 Safe for Everyone With Obesity?

No.

Even when someone meets the BMI criteria, the medicine may not necessarily be appropriate.

Before prescribing, an endocrinologist may review:

Medical history
Family history
Current medications
BMI
Waist circumference
Blood pressure
HbA1c
Blood glucose
Lipid profile
Liver function
Kidney function
Gastrointestinal symptoms
Eating patterns
Previous weight-loss attempts
Pregnancy status where relevant
Cardiovascular risk

This is why GLP-1 medicines should not be started simply because a friend, celebrity or social-media influencer is taking one.

What Tests Are Needed Before Starting a GLP-1 Medicine?

There is no single universal test panel for every patient.

The evaluation depends on your medical history.

An endocrinologist may consider:

Blood glucose and HbA1c

To identify diabetes or prediabetes.

Lipid profile

To evaluate cholesterol and cardiovascular risk.

Kidney function

Particularly important when other medications or dehydration risk are present.

Liver assessment

Especially when metabolic dysfunction-associated steatotic liver disease is suspected.

Blood pressure

Hypertension frequently accompanies obesity.

Thyroid evaluation when clinically indicated

Not every person with obesity needs extensive thyroid testing, but thyroid disease should be considered when symptoms or clinical findings suggest it.

Sleep apnea assessment

Snoring, daytime sleepiness and other symptoms may warrant evaluation for obstructive sleep apnea.

What Happens During a GLP-1 Consultation?

A good obesity consultation should be more than:

“What is your weight?”

A comprehensive assessment may include:

1. Understanding your weight history

When did weight gain begin?
What treatments have you previously tried?
Have you repeatedly lost and regained weight?

2. Looking for medical causes

Certain endocrine and medication-related factors can contribute to weight gain.

3. Assessing complications

Diabetes, hypertension, fatty liver, sleep apnea and other metabolic conditions are important.

4. Discussing treatment goals

Your goal might be:

5% weight loss
10% weight loss
15% or more
Better diabetes control
Reduced blood pressure
Improved mobility
Better sleep

5. Choosing the appropriate treatment

A GLP-1 or GIP/GLP-1 medicine may be appropriate—or another treatment may be better.

Which GLP-1 Medicine Is Best for Weight Loss?

There is no single best GLP-1 medicine for everyone.

Some commonly used options include:

Semaglutide

A GLP-1 receptor agonist.

Liraglutide

Another GLP-1 receptor agonist used in specific indications.

Tirzepatide

A dual GIP/GLP-1 receptor agonist.

Current 2026 ADA guidance identifies semaglutide and tirzepatide as high-efficacy options for people with diabetes and overweight or obesity when clinically appropriate.

The choice depends on the patient rather than simply selecting the strongest drug.

Do You Need to Have a Very High BMI to Take GLP-1 Medicines?

Not necessarily.

A patient with BMI ≥30 kg/m² may meet obesity criteria for pharmacological treatment.

A patient with BMI ≥27 kg/m² may also qualify when appropriate weight-related medical conditions are present, depending on the specific medicine and regulatory indication.

Indian clinical guidance may use lower BMI thresholds when metabolic complications are present, reflecting the increased metabolic risk seen at lower BMI in Asian populations.

Therefore, BMI should be interpreted in the context of ethnicity, body composition and metabolic health, rather than used in isolation.

What Are the Common Side Effects?

The most common side effects are gastrointestinal:

Nausea
Vomiting
Diarrhea
Constipation
Bloating
Abdominal discomfort
Indigestion
Reduced appetite

These symptoms are often more noticeable during the initial phase or after increasing the dose.

WHO identifies nausea, vomiting, constipation and diarrhea among the common adverse effects of GLP-1 therapies.

Gradual dose escalation and individualized treatment can help improve tolerability.

Does Everyone Lose Weight With GLP-1 Medicines?

No.

Response varies.

Factors include:

Medicine used
Dose
Treatment duration
Starting weight
Diabetes status
Lifestyle
Adherence
Genetics and individual biology

The WHO notes that most people treated with GLP-1 therapies lose at least 5% of body weight, but individual responses differ.

If treatment is not producing the expected response, the doctor may reassess:

Diagnosis
Adherence
Dose
Diet
Physical activity
Other medications
Underlying medical conditions
Whether another treatment would be more appropriate

Do GLP-1 Medicines Replace Diet and Exercise?

No.

Medication works best as part of a comprehensive weight-management programme.

A successful plan may include:

Medication + nutrition + physical activity + resistance training + sleep + behavioral support

The WHO specifically recommends combining GLP-1 therapy with healthy eating, physical activity and professional support.

How Can You Get Better Results From GLP-1 Treatment?

The goal should not be to take the highest possible dose or lose weight as quickly as possible.

Instead, focus on:

Adequate protein

Important for preserving lean muscle during weight loss.

Resistance training

Helps maintain strength and muscle mass.

Balanced nutrition

Choose nutrient-dense foods rather than simply eating as little as possible.

Adequate hydration

Particularly important if gastrointestinal symptoms occur.

Sleep

Poor sleep can affect appetite and metabolic health.

Regular follow-up

Your doctor can assess weight, body composition, metabolic parameters, side effects and treatment response.

What Happens If You Stop GLP-1 Treatment?

This is something every patient should understand before starting treatment.

Obesity is a chronic and relapsing condition.

After stopping effective obesity medication, some patients regain weight.

The 2026 ADA Standards note that discontinuing chronic obesity pharmacotherapy often leads to recurrence of weight gain and worsening or re-emergence of cardiometabolic risk factors.

Therefore, the treatment plan should include a discussion about long-term weight maintenance, not only the first few months.

GLP-1 Medicines Are Not for Cosmetic Weight Loss

This is perhaps the most important message.

GLP-1 medicines should not be viewed as:

“I want to lose 5 kg before a wedding.”

They are medical treatments intended for people who meet appropriate clinical criteria.

The goal is to improve:

Obesity
Metabolic health
Diabetes control
Cardiovascular risk
Blood pressure
Lipid profile
Physical function
Quality of life

Frequently Asked Questions

Can a person without diabetes take GLP-1 for weight loss?

Yes. Some GLP-1-based medicines and tirzepatide are approved for chronic weight management in appropriately selected people with obesity or overweight with relevant medical conditions.

Can I take GLP-1 if my BMI is 28?

Potentially, particularly if you have a weight-related condition such as diabetes, hypertension, dyslipidemia or sleep apnea. Eligibility depends on the specific medicine and applicable clinical/regulatory criteria.

Can I take GLP-1 if I only want to lose 5 kg?

Not necessarily. GLP-1 medicines are prescription treatments for specific medical indications and are not intended simply for cosmetic weight loss.

Can someone with diabetes take semaglutide or tirzepatide?

Yes. These medicines can be important options for selected people with type 2 diabetes, particularly when overweight or obesity is also present.

Can I take GLP-1 during pregnancy?

GLP-1 medicines should not be used for weight loss during pregnancy. If you are pregnant, planning pregnancy or breastfeeding, discuss this with your doctor before using any weight-management medicine.

Is GLP-1 treatment lifelong?

Not necessarily for every individual, but obesity often requires long-term management. Stopping effective medication can result in weight regain, so the long-term plan should be discussed with your endocrinologist.

Should I buy GLP-1 injections online?

Be very cautious. WHO has warned that increasing global demand has contributed to falsified and substandard GLP-1 products. These medicines should be obtained through regulated channels and prescribed by qualified healthcare professionals.

Final Takeaway

GLP-1 agonists can be highly effective medicines for obesity, overweight with weight-related complications, and type 2 diabetes with overweight or obesity—but they are not suitable for everyone.

A person may be a candidate for GLP-1-based treatment when they have obesity or qualifying overweight with relevant medical conditions, but the decision should be based on a complete medical assessment rather than BMI alone.

The right treatment considers:

BMI + metabolic health + medical history + medications + treatment goals + safety + long-term plan

If you are considering GLP-1 injections for weight loss, do not start treatment simply because someone else is taking the medicine.

Speak with an endocrinologist to determine whether GLP-1 treatment is appropriate for you.

About Dr. Moxit Shah

Dr. Moxit Shah, DM Endocrinologist in Ahmedabad, provides specialist care for diabetes, thyroid disorders, obesity, medical weight management and other endocrine conditions.

For patients considering GLP-1 agonists, semaglutide or tirzepatide for weight loss, individualized assessment and regular follow-up are important for safe and effective treatment.